Self-reported treatment-emergent adverse events were captured at each follow-up visit: nausea and vomiting were more common among the CYP2B6 slow metabolizers (5/45; 11.1%), and insomnia was more common among the CYP2B6 extensive metabolizers (5/49; 10.2%) and in the dolutegravir arm (22/342; 6.4%) (Supplementary Table 2). The gene discussed is CYP2B6; the disease is insomnia measurement.